SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery
and development of innovative medicines based on novel immunological pathways, today announced that it will report its first
quarter financial results on Monday, May 14, 2018 before the open of the U.S. financial markets. Company management will host a
conference call and webcast on Monday, May 14, 2018 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss the results and
provide a corporate update.
Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and
using conference ID 8255679.
The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at
least 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways
in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs
based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage
ATYR1923 candidate is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s
preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the
immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250
issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein
compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
IMMEDIATE RELEASE
Contact:
Mark Johnson
Sr. Director, Investor Relations
mjohnson@atyrpharma.com
858-223-1163
